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A B S T R A C T
Background: The recent molecular epidemiology of ESBL-producing Escherichia coli infection in two
Korean community hospitals was evaluated in this prospective observational study.
Methods: We collected non-duplicated E. coli isolates from consecutive, sequentially encountered
patients with community-onset episodes between March and April 2016 in two community hospitals in
Gyeonggi-do province, Korea. We studied the prevalence, clinical characteristics and molecular
epidemiology of E. coli sequence type 131 (ST131) isolated from the community.
Results: From a total of 213 E. coli isolates collected from the community, 94 (44.1%) were community-
onset healthcare-associated isolates and 119 (55.9%) were community-associated isolates, of which
urinary tract infection was the majority. A total of 55 (25.8%) of the 213 E. coli isolates were conﬁrmed to
have ESBL genes, which were mainly CTX-M types such as CTX-M-14 and CTX-M-15. There was no
difference in the proportion of globally epidemic ST131 clones or that of O25, O16, H30, or H30Rx
subclones between community-associated and community-onset healthcare-associated isolates.
Conclusions: In this study, considerable ST131 E. coli isolations in the community were observed and
about half of them were related to the history of a visit to the healthcare facilities, indicating the spread
of multidrug-resistant E. coli to the community via healthcare facilities.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Extraintestinal pathogenic Escherichia coli (ExPEC) infection is a
signiﬁcant public health problem, consisting primarily of urinary
tract infections.1 Of ExPEC infections, sequence type 131 (ST131) E.
coli has played a major part in the global dissemination of speciﬁc
traits for epidemic expansion such as greater virulence and
multidrug resistance, including extended-spectrum b-lactamase
(ESBL) and ﬂuoroquinolone resistance.2 The well-deﬁned char-
acteristics of this clone consist of phylogenetic B2, serotype O25,
ﬁmH type H30 and ST131 according to multilocus sequence typing
(MLST) based on Achtman.3 Especially, single expansion of the* Corresponding author. Department of Laboratory Medicine and Research
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resistance and CTX-M-15 ESBL and comprises most ST131 clones.4
Another ST131 E. coli subclone was recently reported, namely, the
serogroup O16, which shows resistance to ampicillin, gentamicin,
and trimethoprim-sulfamethoxazole and is susceptible to ﬂuor-
oquinolones and extended-spectrum cephalosporins.5
The aims of this study were to evaluate the recent molecular
epidemiology of ESBL-producing E. coli acquisitions from two
community hospitals, and to assess the differences between
community-associated and community-onset healthcare-associ-
ated isolates in a prospective, multicenter, observational study.6
2. Materials and methods
2.1. Bacterial isolates
We collected non-duplicated E. coli isolates from consecutive,
sequentially encountered patients with community-onsetciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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hospitalization between March and April 2016 in two community
hospitals in Gyeonggi-do province, Korea (742 beds, Goyang-si;
132 beds, Yongin-si). Healthcare-acquired E. coli isolates that were
collected after 48 hours of admission were excluded. The study
was approved by institutional review boards as required by local
hospital policy (NHIMC 2016-02-006).
2.2. Deﬁnitions
Sites of acquisition (community-associated or healthcare-
associated) were determined as described by Friedman with some
modiﬁcations.7,8 Healthcare-associated infections have any of
following histories: attended a hospital or hemodialysis clinic or
received intravenous chemotherapy in the 30 days before the
infection; hospitalized in an acute care hospital for 2 or more days
in the 90 days before the infection. Others were deﬁned as
community-associated infection. The diagnosis of infection was
made based on clinical, bacteriological, and radiological investiga-
tions.9
2.3. Microbiological analysis
Identiﬁcation and susceptibility testing were performed using
the Vitek 2 automated analyzer system (bioMe´rieux, Marcy
l’E’toile, France) with a VITEK AST2 N212 card (bioMe´rieux).
Antibiotic susceptibility was interpreted using CLSI criteria.10 ESBL
genotype was determined by PCR and sequencing.11 For the
detection of ST131, all isolates were screened by PCR for O16-
ST131 and O25-ST131.5 FimH type and H30Rxwere determined by
PCR and sequencing.4,12Table 1
Types of infections, extended-spectrum b-lactamase (ESBL) types, and the prevalence o
community-associated (CA) Escherichia coli episodes (N=213)
HA (N=94)
Status of infection
Infection 74 (78.7%)
Colonization 17 (18.1%)
Indeterminate 3 (3.1%)
Type of infection
Urinary tract infection 46 (62.2%)
Bacteremia 18 (24.3%)
Abscess/wound 8 (10.8%)
Others 2 (2.7%)
ESBL by genotype 25 (26.6%)
CTX-M group CTX-M-15 (N=9), CTX-M-14 (N=10),
CTX-M-27 (N=5), other (N=1)
SHV group Not detected
TEM group Not detected, TEM-1 [1_TD$DIFF]a (N=2)
ST131 subclone 26 (27.7%)
O16-ST131 10 (10.6%)
O25-ST131 16 (17.1%)
H30 15/16 (93.8%)
H30Rx 5/15 (33.3%)
Non-ST131 68 (72.3%)
N, number; Chi-square test or Fisher’s exact test.
a Narrow-spectrum b-Lactamase.
Table 2
Extended-spectrum b-lactamase (ESBL) types and the prevalence of sequence type 13
ST131 (O25+O16) O25
ESBL positive (%) 28/58 (48.3%) 23/41 (56.1%)
CTX-M group
CTX-M-15 16 16
CTX-M-14 9 4
CTX-M-27 3 3
N, number.
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SAS software, version 9.2 was used for the statistical analysis
(SAS Institute, Cary, NC, USA). Comparisons of proportions were
tested using the Chi-square test or Fisher’s exact test with the level
of signiﬁcance set as P value < 0.05.
3. Results
A total of 213 community-onset isolates were identiﬁed,
consisting of 94 (44.1%) healthcare-associated (HA) isolates and
119 (55.9%) community-associated (CA) isolates, the majority of
which were from urinary tract infections. No statistically signiﬁ-
cant difference was found in either infection or colonization status
of CA isolates, compared to that of HA isolates (P = 0.701, Table 1).
Although urinary tract infection was the most common type in
both groups, bacteremia was more frequently encountered in the
HA group than in the CA group and the two groups were different
in the type of infection (P < 0.0001, Table 1). A total of 55 E. coli
isolates (25.8%, 55/213) had ESBL genes, whichweremainly CTX-M
types such as CTX-M-15 and CTX-M-14. In addition, there was no
statistically signiﬁcant difference in ESBL genotypes between the
CA and HA groups (P = 0.8752, Table 1).
Among CA isolates, 26.9% (32/119) were caused by the globally
epidemic ST131 strain, which was similar to that of HA isolates
(27.7%, 26/94) and there was no statistically signiﬁcant difference
in the proportion of globally epidemic ST131 clone or O25, O16,
H30, or H30Rx subclones between CA and HA isolates (Table 1).
According to ST131 subclones, ESBL positive rates and types
were different (Table 2). ST131-O25H30Rx subclones most
commonly produced ESBLs, all of which were CTX-M-15 types,f sequence type 131 (ST131) of community-onset healthcare-associated (HA) and
CA (N=119) P
0.7016
98 (82.4%)
19 (16.0%)
2 (1.7%)
<0.0001
78 (79.6%)
9 (9.2%)
1 (1.0%)
10 (10.2%)
30 (25.2%) 0.8752
CTX-M-15 (N=17), CTX-M-14 (N=9),
CTX-M-27 (N=1), other (N=3)
Not detected
Not detected, TEM-1a (N=1)
32 (26.9%) 1.0000
7 (5.9%) 0.2152
25 (21%) 0.4893
20/25 (80%) 0.3759
11/20 (55%) 0.3064
87 (73.1%) 1.0000
1 (ST131) in community-onset Escherichia coli episodes (N=58)
H30 H30Rx O16
20/35 (57.1%) 13/16 (81.3%) 5/17 (29.4%)
14 13 0
4 0 5
2 0 0
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Table 3
Antimicrobial resistance rate (%) of Escherichia coli isolated from two community hospitals
Antimicrobial agents Resistance rate (%)
Site of acquisition Sequence type (ST)
HAa (n=93) CA (n=119) ST131-O25-H30
(n=35)
ST131-O25-H30Rx
(n=16)
ST131-O16
(n=17)
All ST131
(n=58)
Other STs
(n=154)
Ampicillin 70 68 83 94 65 79 65
Piperacillin 69 64 80 88 65 78 62
Ampicillin/sulbactam 33 25 40 44 29 35 27
Cefoxitin 4 2 3 6 0 3 3
Cefotaxime 30 27 60 88 29 50 20
Ceftazidime 30 24 57 81 24 47 19
Meropenem 0 0 0 0 0 0 0
Imipenem 0 0 0 0 0 0 0
Ciproﬂoxacin 39 44 100 100 18 67 32
Gentamicin 23 25 51 56 35 43 17
Tobramycin 13 11 31 38 24 28 6
Amikacin 0 0 0 0 0 0 0
Cotrimoxazole 33 25 49 44 41 45 23
HA, community-onset healthcare-associated; CA, community-associated; all ST131 include O25-H30, O25-nonH30, and O16.
a One isolate was excluded from the antimicrobial susceptibility test.
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which were CTX-14 types.
Antimicrobial resistance patterns showed distinct character-
istics according to ST131 subclone, and in particular the H30Rx
group showed prominent resistance to ﬂuoroquinolones such as all
resistant to ciproﬂoxacin or levoﬂoxacin and 88% resistance to
cefotaxime due to CTX-M type ESBL production (Table 3). However,
the antimicrobial resistance rates were similar in the HA and CA
groups (Table 3).
4. Discussion
It is well known that the majority of community-onset E. coli
isolates come from urinary tract infections,13 and our study also
showed that urinary tract infection was the most common type.
Recently, the emergence of community-onset bacteremia via ESBL-
producing E. coli has become a major concern.8,14 In this study,
community-onset bacteremiawasmore frequently encountered in
the HA group (possibly not as healthy as the CA group), suggesting
that not only microbiological factors but also the impact of host
factors are important for severe types of infections such as
bacteremia.
Extended-spectrum b-lactamase (ESBL)-producing E. coli has
become widespread in hospitals around the world since the late
1980s,15 but a sudden worldwide increase in the mid 2000s is
mainly due to sequence type (ST) 131 with resistance to quinolone
and 3rd generation cephalosporin, which was suggested as the
main cause of the spread of ESBL producing E. coli in the
community.3,16 Not only community-onset E. coli infection but
also asymptomatic carriage among health individuals without
prior exposure to antibiotics increased.17 Our study showed a high
prevalence of ESBLs, mainly CTX-M, among community-onset E.
coli isolates in Korean community hospitals. In the Asia-Paciﬁc
region, higher rates of ESBL-producing E. coli were observed in
countries like China, India and Thailand, compared to Korea.18
The incidence of notorious epidemic resistant clones of E. coli
varies over time and geographic regions, and the ST131 E. coli
clonal group has been evolving through the acquisition of new
mobile elements.19 Continuous monitoring of major epidemic
resistance clones is needed for updated information regarding the
status of ST 131 E. coli. In the most recent molecular epidemiology
data of ST131 E. coli in Korea, the ST131 clonal group comprised
21% (57/268) of all E. coli isolates, 37% (21/57) of whichwereH30Rx
subclones.20 This study included both healthcare-onset andDownloaded for Anonymous User (n/a) at KESLI - Yonsei University Med
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cultures between September 2012 and January 2013. Although
direct comparisons are inadequate, considering different acquisi-
tion sites (our study includes only E. coli isolates from the
community), our study showed that 27% (58/213) of E. coli isolates
from the community belonged to the globally epidemic ST131
strain, 28% (16/58) of which were H30Rx subclones. Therefore
ST131 E. coli infections in the community are already considerable
in Korea, and ST131-O25H30Rx subclones could be considered
potential driving factors, with their high ESBL (mainly CTX-M type)
production rates as well as successful traits related to extensive
virulence gene content and ongoing transmission.2
Recently multiple sources of ST131 E. coli in the community
have been suspected, including livestock, companion animals,
sewage, waste water, and recreational waterways.21,22 This ‘One
Health’ concept, which recognizes that the health of humans is
connected to the health of animals and the environment, may be
useful for promoting cross-sectorial collaborations and represents
a possible solution for preventing the spread of multidrug
resistance in the community. Nevertheless, it is important to
emphasize that ST131 E. coli accounts for a large proportion of HA
infections.23 In our study, 44.1% (94/213) of patients hadHA factors
such as recent visits to a healthcare facility. Thus, It is reasonable to
assume that the burden of ESBL producing E. coli in the community
is affected by healthcare facilities (and vice versa) in a ‘revolving
door’ pattern,24 similar to that of CA methicillin-resistant
Staphylococcus aureus.25
In this study, considerable community-onset acquisitions of
ST131 E. coli from two community hospitals were observed, and
about half of them had history related to healthcare facilities,
indicating the spread of multidrug-resistant E. coli to the
community via healthcare facilities.
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